REGENERON PHARMACEUTICALS, INC.

REGN · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $80.7B · 15,410 employees
137
SEC Filings
$748.87
Close 2026-04-10
15,410
Employees

Business Summary

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. Its marketed products include EYLEA HD and EYLEA (aflibercept) for eye diseases, Dupixent (dupilumab) for allergic and inflammatory diseases, Libtayo (cemiplimab) for cancers, Praluent (alirocumab) for cardiovascular risk, Kevzara (sarilumab) for rheumatoid arthritis, and others. The company reported revenues of $14.3 billion in 2024.

Latest Stock Quote

REGN 2026-04-10 $748.87 O:$771.48 H:$771.48 L:$739.09 Vol:0.8M VWAP:$749.5241
origin leaf: 6ff476776f39928d303a49904202f56cd205e9c858b35eb33538db1e294c63f7

Next Earnings

Q2 FY2026 — expected 2026-07-23

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionREGNdiscussed_in_filing Cybersecurity
topic_mentionREGNdiscussed_in_filing Trusted Computing
topic_mentionREGNdiscussed_in_filing Blockchain & Crypto
topic_mentionREGNdiscussed_in_filing Supply Chain
topic_mentionREGNdiscussed_in_filing Regulation
topic_mentionREGNdiscussed_in_filing Healthcare & Bio
topic_mentionREGNdiscussed_in_filing Sovereign & Government
topic_mentionREGNdiscussed_in_filing Cybersecurity
topic_mentionREGNdiscussed_in_filing Trusted Computing
topic_mentionREGNdiscussed_in_filing Blockchain & Crypto
topic_mentionREGNdiscussed_in_filing Supply Chain
topic_mentionREGNdiscussed_in_filing Regulation
topic_mentionREGNdiscussed_in_filing Healthcare & Bio
topic_mentionREGNdiscussed_in_filing Sovereign & Government
topic_mentionREGNdiscussed_in_filing Cybersecurity
topic_mentionREGNdiscussed_in_filing Trusted Computing
topic_mentionREGNdiscussed_in_filing Blockchain & Crypto
topic_mentionREGNdiscussed_in_filing Supply Chain
topic_mentionREGNdiscussed_in_filing Regulation
topic_mentionREGNdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-042025-12-310000872589-26-000008EDGAR93K words
2025-02-052024-12-310001804220-25-000011EDGAR—
2024-02-052023-12-310001804220-24-000009EDGAR—
2023-02-062022-12-310001804220-23-000008EDGAR—
2022-02-072021-12-310001804220-22-000007EDGAR—
2021-02-082020-12-310001804220-21-000008EDGAR—
2020-02-072019-12-310001532176-20-000008EDGAR—
2019-02-072018-12-310001532176-19-000009EDGAR—
2018-02-082017-12-310001532176-18-000013EDGAR—
2017-02-092016-12-310001532176-17-000008EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-10-282025-09-300000872589-25-000028EDGAR58K words
2025-08-012025-06-300000872589-25-000019EDGAR—
2025-04-292025-03-310001804220-25-000022EDGAR—
2024-10-312024-09-300001804220-24-000040EDGAR—
2024-08-012024-06-300001804220-24-000028EDGAR—
2024-05-022024-03-310001804220-24-000017EDGAR—
2023-11-022023-09-300001804220-23-000031EDGAR—
2023-08-032023-06-300001804220-23-000023EDGAR—
2023-05-042023-03-310001804220-23-000016EDGAR—
2022-11-032022-09-300001804220-22-000031EDGAR—
2022-08-032022-06-300001804220-22-000023EDGAR—
2022-05-042022-03-310001804220-22-000015EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-080001104659-26-040661EDGAR—
2026-01-300000872589-26-000004EDGAR10K words
2026-01-120001104659-26-002691EDGAR—
2025-10-280000872589-25-000026EDGAR—
2025-10-060001104659-25-096921EDGAR—
2025-08-010000872589-25-000017EDGAR—
2025-06-180001104659-25-060637EDGAR—
2025-04-290001804220-25-000020EDGAR—
2025-02-040001804220-25-000007EDGAR—
2025-01-130001104659-25-002826EDGAR—

137 total filings indexed. 105 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

eye-diseases allergic-and-inflammatory-diseases cancer-/-oncology cardiovascular-and-metabolic-diseases neurological-diseases hematologic-conditions infectious-diseases rare-diseases velocimmune velocigene velocimab velocisuite velocimouse veloci-bi velocit velocihum altibodies

Company Identity

CIK0000872589
TickerREGN
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedNY
Websitehttps://www.regeneron.com
Listed1991-04-02

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 333516226576381f5682fe40d4be9039d9c529826a1f39c78fe5cf3e862d0cfe
parent: 3bd1e5c66f4e5da74504bd177c77574e161bcf9b550b27ccf454adef07483ac8
content hash: 345823975a21ef69c0b3bd271f8b8eb467cb14c76b516286637c17f52d54b137
signed: 2026-04-13T04:47:09.743Z
sources: 23 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf